January 2025 Price Concessions 2nd Update
THIS CONTENT HAS NOW EXPIRED
Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (17/01/2025) announced the following list of price concessions for January 2025:
Drug | Pack size | Price concession |
Acamprosate 333mg gastro-resistant tablets | 168 | £21.90 |
Bimatoprost 300micrograms/ml / Timolol 5mg/ml eye drops | 3 | £8.83 |
Captopril 25mg tablets | 56 | £21.19 |
Codeine 15mg/5ml linctus | 200 | £16.50 |
Fenofibrate micronised 160mg tablets | 28 | £3.50 |
Hydroxocobalamin 1mg/1ml solution for injection ampoules | 5 | £11.73 |
Lactulose 3.1-3.7g/5ml oral solution | 500 | £4.95 |
Mometasone 0.1% ointment | 30 | £3.10 |
Ondansetron 8mg tablets | 10 | £4.29 |
Rivastigmine 3mg capsules | 28 | £2.43 |
Trihexyphenidyl 2mg tablets | 84 | £3.14 |
Trospium chloride 20mg tablets | 60 | £11.49 |
For the full list of price concessions granted for January 2025 so far please visit our price concession hub page here.
No additional endorsements are required for price concessions. A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
We encourage pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website. Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. We will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
Please subscribe to our mailing list to receive email updates of any price concessions.
Further information on price concessions and FAQs about the process involved can be found on our website (cpe.org.uk/priceconcessions) Please see our latest funding and reimbursement short videos for further information on the recent changes to the price concession process.